| Literature DB >> 27788489 |
Zheng Lin1, Weilin Chen2, Yuanmei Chen3, Xiane Peng1,4, Kunshou Zhu3, Yimin Lin1, Qiaokuang Lin2, Zhijian Hu1,4.
Abstract
Lymph node metastasis (LNM) is one of the major prognostic factors for esophageal squamous cell carcinoma (ESCC). However there is no consensus regarding the prognostic significance of the location of LNM. Therefore, a novel classification was proposed to identify the lymph node (LN) stations which may be useful in predicting prognosis. A total of 260 ESCC patients were enrolled in this prospective study. The prognostic values of LNM in different lymph node (LN) stations were evaluated by random survival forests (RSF). Their prognostic significance was examined by Cox regression and receiver operating characteristic curve (ROC). The three most frequently involved LN stations were station 16 (24.49%), station 1 (22.22%) and station 2 (21.05%). Stations 1, 2, 8M, 8L and 16 were grouped as dominant LN stations (DLNS) which showed higher values in predicting overall survival (OS) and disease-free survival (DFS) than the remaining LN stations, which we define as non-dominant LN stations (N-DLNS). LNM features of DLNS (number of positive LN stations, number of positive LNs and LN ratio), but not those from N-DLNS, served as independent prognostic factors (P<0.05) whenever used alone or when combined with factors from N-DLNS. Furthermore, the area under ROC indicated that DLNS is a more accurate prediction than N-DLNS (P<0.05). This study demonstrated the value of LNM in DLNS in predicting prognosis in surgical ESCC patients, which outperformed those from N-DLNS. Therefore, the method of dominant and non-dominant classification may serve as an additional parameter to improve individualized therapeutic strategies.Entities:
Keywords: ESCC; LNM; RSF; prognosis
Mesh:
Year: 2016 PMID: 27788489 PMCID: PMC5342812 DOI: 10.18632/oncotarget.12842
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Descriptions of demographic, clinical and pathological characteristics for the 260 patients included in this study
| Characteristic | Total (n=260) | |
|---|---|---|
| n | % | |
| Age (year) | ||
| Median (P25, P75) | 61 (52, 67) | |
| Sex | ||
| Male | 201 | 77.3 |
| Female | 59 | 22.7 |
| Tumor location | ||
| CE/UTE | 28 | 10.8 |
| MTE | 173 | 66.5 |
| LTE | 59 | 22.7 |
| Tumor length (cm) | ||
| Median (P25, P75) | 4.0 (3.0, 4.5) | |
| Primary tumor (pT) | ||
| pT1 | 30 | 11.5 |
| pT2 | 44 | 16.9 |
| pT3 | 164 | 63.1 |
| pT4 | 22 | 8.5 |
| Regional lymph nodes (pN) | ||
| pN0 | 119 | 45.8 |
| pN1 | 67 | 25.1 |
| pN2 | 54 | 20.8 |
| pN3 | 20 | 7.7 |
| Distant metastasis (M) | ||
| M0 | 260 | 100 |
| M1 | 0 | 0 |
| Histologicgrade (pG) | ||
| pG1 | 79 | 30.4 |
| pG2 | 148 | 56.9 |
| pG3 | 18 | 6.9 |
| Tumor stage (pTNM) | ||
| 0 | 3 | 1.2 |
| IA | 7 | 2.7 |
| IB | 28 | 10.8 |
| IIA | 37 | 14.2 |
| IIB | 52 | 20.0 |
| IIIA | 61 | 23.5 |
| IIIB | 37 | 14.2 |
| IIIC | 35 | 13.5 |
| LVI | ||
| Yes | 71 | 27.3 |
| No | 189 | 72.7 |
| PNI | ||
| Yes | 62 | 23.8 |
| No | 198 | 76.2 |
| Type of lymphadenectomy | ||
| 3-FLND | 153 | 58.8 |
| 2-FLND | 107 | 41.2 |
| Residual tumor (R) | ||
| Rx | 5 | 1.9 |
| R0 | 251 | 96.5 |
| R1 | 4 | 1.5 |
| Anastomotic leak | ||
| Yes | 52 | 20.0 |
| No | 191 | 73.5 |
| Postoperative infection* | ||
| Yes | 124 | 47.7 |
| No | 119 | 45.8 |
| Chemotherapy | ||
| Yes | 74 | 28.5 |
| No | 186 | 71.5 |
| Radiotherapy | ||
| Yes | 59 | 22.7 |
| No | 201 | 77.3 |
| Harvested lymph nodes (HLNs) | ||
| Median (P25, P75) | 35 (25, 46) | |
| Positive lymph nodes (PLNs) | ||
| Median (P25, P75) | 1 (0, 3) | |
CE, cervical esophagus; UTE, upper thoracic esophagus; MTE, middle thoracic esophagus; LTE, lower thoracic esophagus; LVI, lymphovascular invasion; PNI, perineural invasion; 3-FLND, three-field lymph node dissection; 2-FLND, two-field lymph node dissection.
Comparisonsof LNM incidence in specific regional lymph node stations across CE/UTE, MTE and LTE
| LN station | CE/UTE (n=28) | MTE (n=173) | LTE (n=59) | Total (n=260) | Exact P Value | Trend P Value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients with PLN | Number of patients with HLN | Prevalence of LNM (%) | Number of patients with PLN | Number of patients with HLN | Prevalence of LNM (%) | Number of patients with PLN | Number of patients with HLN | Prevalence of LNM (%) | Number of patients with PLN | Number of patients with HLN | Prevalence of LNM (%) | |||
| 1 | 7 | 18 | 38.89 | 24 | 105 | 22.86 | 3 | 30 | 10.00 | 34 | 153 | 22.22 | 0.066 | 0.023 |
| 2 | 7 | 24 | 29.17 | 32 | 143 | 22.38 | 5 | 42 | 11.90 | 44 | 209 | 21.05 | 0.174 | 0.093 |
| 3p | 2 | 18 | 11.11 | 12 | 105 | 11.43 | 0 | 24 | 0.00 | 14 | 147 | 9.52 | 0.204 | 0.196 |
| 4 | 2 | 11 | 18.18 | 8 | 88 | 9.09 | 1 | 22 | 4.55 | 11 | 121 | 9.09 | 0.358 | 0.351 |
| 5 | 0 | 1 | 0.00 | 2 | 21 | 9.52 | 0 | 6 | 0.00 | 2 | 28 | 7.14 | 1.000 | 1.000 |
| 6 | 0 | 1 | 0.00 | 1 | 10 | 10.00 | 0 | 3 | 0.00 | 1 | 14 | 7.14 | 1.000 | 1.000 |
| 7 | 1 | 23 | 4.35 | 17 | 141 | 12.06 | 5 | 49 | 10.20 | 23 | 213 | 10.80 | 0.662 | 0.700 |
| 10 | 0 | 19 | 0.00 | 17 | 145 | 11.72 | 3 | 49 | 6.12 | 20 | 213 | 9.39 | 0.223 | 1.000 |
| 8M | 2 | 17 | 11.76 | 25 | 107 | 23.36 | 7 | 40 | 17.50 | 34 | 164 | 20.73 | 0.509 | 1.000 |
| 8L | 2 | 14 | 14.29 | 21 | 116 | 18.10 | 12 | 45 | 26.67 | 35 | 175 | 20.00 | 0.444 | 0.233 |
| 9 | 1 | 4 | 25.00 | 6 | 39 | 15.38 | 2 | 17 | 11.76 | 9 | 60 | 15.00 | 0.708 | 0.744 |
| 15 | 0 | 4 | 0.00 | 1 | 35 | 2.86 | 1 | 14 | 7.14 | 2 | 53 | 3.77 | 0.568 | 0.528 |
| 16 | 3 | 24 | 12.50 | 37 | 162 | 22.84 | 20 | 59 | 33.90 | 60 | 245 | 24.49 | 0.088 | 0.035 |
| 17 | 2 | 17 | 11.76 | 12 | 81 | 14.81 | 7 | 37 | 18.92 | 21 | 135 | 15.56 | 0.783 | 0.564 |
| 18 | 0 | 9 | 0.00 | 4 | 65 | 6.15 | 0 | 26 | 0.00 | 4 | 100 | 4.00 | 0.710 | 0.662 |
| 19 | 0 | 4 | 0.00 | 1 | 22 | 4.55 | 0 | 8 | 0.00 | 1 | 34 | 2.94 | 1.000 | 1.000 |
| 20 | 0 | 4 | 0.00 | 1 | 19 | 5.26 | 0 | 10 | 0.00 | 1 | 33 | 3.03 | 1.000 | 1.000 |
CE, cervical esophagus; UTE, upper thoracic esophagus; MTE, middle thoracic esophagus; LTE, lower thoracic esophagus; PLN, positive lymph node; HLN, harvested lymph node; LNM, lymph node metastasis;
2-sided Fisher's exact test for the incidence of PLN between three different locations
2-sided test of linear by linear association between the location (as ordinal variable) and incidence of LNM
P<0.05.
Figure 1The pattern of lymph node metastasis (LNM) in regional nodal stations
A. Multiple line chart of incidence of LNM in varying nodal stations separated by tumor location. The light gray, dark gray, black and dark red lines indicate tumor was located at CE/UTE, MTE, LTE and all locations, respectively. No significant difference of incidence of LNM was observed at any LN stations for the three locations. B. The pattern of multiple lymph node metastatic involvement in all patients, and separated by tumor locations C. CE/UTE, D. MTE and E. LTE. Darker color indicates the prevalence in the specific LN station is high, while the lighter color shows low prevalence.
Figure 2The impact of nodal metastasis on survival
Forests plot of 95% confidence intervals of median survival time (MST) of A. overall and B. disease-free survival. The points inside the gray boxes represent the point estimates of the MST, the size of each box is proportionate to the weight of each nodal station, and the horizontal bars denote the 95% CI of MST. Two random survival forest (RSF) models were used for hunting for the important variables associated with C. poor overall and D. disease-free survival. The variables with depth below the thresholds will be selected as the important variables (dark gray dots).
Figure 3Lymph nodes metastasis in dominant lymph node stations (DLNS) serves as a stronger predictor to poorer overall and disease-free survival than non-dominant lymph node stations (N-DLNS)
Overall survival A. and disease-free survival curves B. of patients with DLNS and/or N-DLNS metastasis. Light gray solid, dark gray dashed, dark gray solid and black solid lines represent the pN0, N-DLNS positive only, DLNS positive only, and both positive cases, respectively. The Cox regression adjusted survival functions plotted in C. (overall survival)and D. (disease-free survival) were adjusted for 60-year old male, tumor located at middle thoracic esophagus with length of tumor 3.8 cm, adventitia invasion (pT3), without PNLVI and chemoradiotherapy. ROC curves of variables from DLNS and N-DLNS served as predictors for 4-year overall E, F, and G. or disease-free survival H, I and J. Solid, dashed and dotted lines represent the indicators from total, DLNS, and N-DLNS, respectively.
Multivariate Cox regression results of association of lymph node metastasis (LNM) in dominant lymph node stations (DLNS) and non-dominant lymph node stations (N-DLNS) with prognosis
| Model | Variables | Overall Survival | Disease-free Survival | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI of HR | P Value | HR | 95% CI of HR | P Value | ||
| 1 | pN0 (n=109) | — | — | — | — | — | — |
| N-DLNS(+) only (n=15) | 1.593 | 0.602-4.214 | 0.348 | 1.195 | 0.460-3.103 | 0.714 | |
| DLNS(+) only (n=67) | 1.720 | 1.017-2.911 | 0.043 | 1.767 | 1.099-2.840 | 0.019 | |
| Both(+) (n=56) | 2.852 | 1.635-4.973 | <0.001 | 2.383 | 1.417-4.008 | 0.001 | |
| <0.001 (trend) | 0.001 (trend) | ||||||
| 2 | Number of (+) stations in DLNS | 1.270 | 1.007-1.601 | 0.043 | 1.247 | 1.007-1.545 | 0.043 |
| Number of (+) stations in N-DLNS | 1.220 | 0.950-1.566 | 0.119 | 1.118 | 0.877-1.426 | 0.369 | |
| 3 | Number of PLNs in DLNS | 1.092 | 1.011-1.180 | 0.025 | 1.101 | 1.021-1.187 | 0.012 |
| Number of PLNs in N-DLNS | 1.009 | 0.871-1.169 | 0.903 | 0.964 | 0.832-1.117 | 0.625 | |
| 4 | LNR | 1.582 | 1.039-2.407 | 0.032 | 1.490 | 1.007-2.205 | 0.046 |
| LNR | 1.250 | 0.889-1.738 | 0.185 | 1.068 | 0.778-1.467 | 0.682 | |
| 5 | Number of (+) stations in DLNS | 1.331 | 1.063-1.668 | 0.013 | 1.277 | 1.037-1.573 | 0.021 |
| 6c | Number of PLNs in DLNS | 1.094 | 1.022-1.173 | 0.010 | 1.092 | 1.021-1.169 | 0.011 |
| 7 | LNR | 1.648 | 1.080-2.515 | 0.021 | 1.497 | 1.010-2.218 | 0.044 |
| 8 | Number of (+) stations in N-DLNS | 1.300 | 1.022-1.654 | 0.032 | 1.187 | 0.937-1.503 | 0.155 |
| 9 | Number of PLNs in N-DLNS | 1.078 | 1.039-1.236 | 0.280 | 1.031 | 0.896-1.185 | 0.674 |
| 10 | LNR | 1.315 | 0.938-1.842 | 0.112 | 1.083 | 0.781-1.503 | 0.633 |
Excludes 13 cases (5%) with HLN<16, 10 cases from pN0, 2 cases from N-DLNS(+), and 1 case from DLNS(+) group.
Age (as continuous), sex (female, male), location of tumor (upper, middle, lower), length of tumor (as continuous), pT (I or II, III or IV), PNLVI (no, yes) and chemoradiotherapy (no, yes) were included as covariates in Model 1.
Models 2 to 10 shared the same covariates (age (as continuous), sex (female, male), location of tumor (upper, middle, lower), length of tumor (as continuous), PNLVI (no, yes), TNM (stage I or II, stage III) and chemoradiotherapy (no, yes)).
LNR was categorized into 3 levels (LNR=0, 0
P<0.05.
Comparisons of ROC curves between DLNS and N-DLNS metastasis for 4-year survival
| Survival | Predictor | Number of positive stations | Number of PLN | LNR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AUC (%) | SE (%) | P | AUC (%) | SE (%) | P | AUC (%) | SE (%) | P | ||
| OS | DLNS | 68.24 | 3.59 | 0.062 | 68.27 | 3.57 | 0.043 | 68.14 | 3.56 | 0.047 |
| N-DLNS | 60.96 | 3.27 | 60.43 | 3.34 | 60.58 | 3.34 | ||||
| DFS | DLNS | 68.01 | 3.56 | 0.012 | 68.64 | 3.29 | 0.004 | 68.32 | 3.47 | 0.005 |
| N-DLNS | 58.63 | 3.19 | 58.03 | 3.25 | 58.11 | 3.29 | ||||
OS, overall survival, DFS, disease-free survival; DLNS, dominant lymph node stations; N-DLNS, non-dominant lymph node stations; PLN, positive lymph node.
LNR were categorized into 6 levels (LNR=0, 0
P<0.05.
Comparisons of the features of lymphadenectomy and lymph node metastasis between DLNS and N-DLNS in 138 N+ ESCC patients
| Features | DLNS | N-DLNS | P |
|---|---|---|---|
| Number of HLN | 20 (15, 27) | 16 (10, 22) | <0.001 |
| Number of positive stations | 1 (1, 2) | 1 (0, 1) | <0.001 |
| Number of PLN | 2 (1, 4) | 1 (0, 2) | <0.001 |
| LNR (%) | 9.3 (4.8, 17.6) | 2.8 (0.0, 12.5) | <0.001 |
HLN, harvested lymph nodes; PLN, positive lymph nodes; LNR, lymph node ratio
Exclude the case with HLN<16.
The statistical description of these features were expressed as median (lower quartile, upper quartile).
Paired-samples Wilcoxon sign rank test P value.
P<0.05.